Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy

The purpose of this research study is to understand the mechanism of action of low level light therapy and also potentially yield markers associated with good treatment response. Low-level light therapy is light-based treatment delivered through advance eye-light device. This therapy uses light energy to provide energy to the meibomian gland cells to slow down age-ing, improve tear stability and reduce inflammation.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Dry Eye Dry Eye Syndromes Eye Diseases Eyelid Diseases Lacrimal Apparatus Diseases Meibomian Gland Dysfunction Meibomian Gland Dysfunction (Disorder)

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Singapore Eye Research Insititute

Singapore

Location status: Recruiting

Location contact

Jiayi Lee, MSc

CONTACT

[email protected]

65767200

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Must be eligible for, and have consented for low level light therapy
Must not have presented to the clinic for an acute eye problem such as visual loss or painful eye
Ability to give informed consent.
Age more or equals to 21 years old.

Exclusion criteria

Patients who are unable to or decline to give consent.
Age less than 21 years old.
Patients who presented to the clinic for an acute eye problem such as visual loss or painful eye.
Patients not suitable for low level lighttherapy:

Pregnant
Fitted with pacemakers, metal, electrical, acoustic prosthetics
Epilepsy, cardiac rhythm or frequency disorders
Fever, thrombophlebitis or acute phlebitis of the legs, large-sized varicose veins, or venous surgery within 2 months
Uncontrolled hypertension or severe diabetes
Open wounds on eyelid or skin
Evolving cancer or hepatitis
Blood anticoagulant or coagulation defect

Treatment and study plan

Primary outcomes

Comparing tear proteomics profile in dry eye disease pre-and post-treatment with low level light therapy

Time frame: Baseline visit and Post Baseline visit 3 months (+3 weeks).

Aim 1: Tear proteomic profile of MGD patients with DED pre- and post-treatment with LLLT will be profiled Aim 2: Baseline tear cytokine levels will be measured using the novel Olink 500-plex technology in DED patients with MGD undergoing LLLT

Study contacts

Contact information is provided by the study sponsor or research team.

Jiayi Lee, MSc

CONTACT

[email protected]

Louis Tong Tong, PhD

CONTACT

[email protected]

65767200

Sponsors and collaborators

Lead sponsor

Singapore National Eye Centre

Other Gov

Registry information

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2027
First posted: Jan 9, 2026
Registry last updated: Jan 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting